Efficacy & safety of anti-Trop-2 antibody drug conjugate sacituzumab govitecan (IMMU-132) in heavily pretreated patients with metastatic triple-negative breast cancer

Journal of Clinical Oncology

Volumn 35, Issue 19, 2017, Pages 2141-2148

  Bardia, Aditya ^a,b   Mayer, Ingrid A ^d   Diamond, Jennifer R ^e   Moroose, Rebecca L ^f   Isakoff, Steven J ^a,b   Starodub, Alexander N ^g   Shah, Nikita C ^f   O'shaughnessy, Joyce ^h,i   Kalinsky, Kevin ^j   Guarino, Michael ^l   Abramson, Vandana ^d   Juric, Dejan ^a,b   Tolaney, Sara M ^b,c   Berlin, Jordan ^d   Messersmith, Wells A ^e   Ocean, Allyson J ^k   Awegener, William ^m   Maliakal, Pius ^m   Sharkey, Robert M ^m   Govindan, Serengulam V ^m   Goldenberg, David M ^m   Vahdat, Linda T ^k   more..

^a MASSACHUSETTS GENERAL HOSPITAL CANCER CENTER   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c DANA FARBER CANCER INSTITUTE   (United States)

^d VANDERBILT INGRAM CANCER CENTER   (United States)

^e UNIVERSITY OF COLORADO CANCER CENTER   (United States)

^f UNIVERSITY OF FLORIDA HEALTH   (United States)

^g INDIANA UNIVERSITY HEALTH   (United States)

^h BAYLOR UNIVERSITY MEDICAL CENTER   (United States)

ⁱ Developmental Therapeutics Committee and Co Chair of the Genitourinary Committee   (United States)

^j NewYork Presbyterian Hospital   (United States)

^k WEILL CORNELL MEDICAL COLLEGE   (United States)

^l Cancer Center   (United States)

^m Immunomedics   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALKALINE PHOSPHATASE; BRCA1 PROTEIN; CYCLOPHOSPHAMIDE; ERIBULIN; FIRTECAN; FLUOROPYRIMIDINE; GEMCITABINE; IXABEPILONE; PLATINUM; SACITUZUMAB GOVITECAN; VINORELBINE TARTRATE; ANTIBODY CONJUGATE; ANTINEOPLASTIC AGENT; CAMPTOTHECIN; CELL ADHESION MOLECULE; MONOCLONAL ANTIBODY; TACSTD2 PROTEIN, HUMAN; TUMOR ANTIGEN;

ABDOMINAL PAIN; ADULT; AGED; ALKALINE PHOSPHATASE BLOOD LEVEL; ALOPECIA; ANEMIA; ANOREXIA; ANTIBODY RESPONSE; ANTINEOPLASTIC ACTIVITY; ARTHRALGIA; ARTICLE; BACKACHE; BRAIN DAMAGE; CANCER COMBINATION CHEMOTHERAPY; CHEMOTHERAPY INDUCED EMESIS; CHEMOTHERAPY INDUCED NAUSEA AND VOMITING; CONSTIPATION; DEHYDRATION; DIARRHEA; DIZZINESS; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DYSPNEA; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; HEADACHE; HUMAN; HYPERGLYCEMIA; HYPOKALEMIA; HYPOMAGNESEMIA; HYPOPHOSPHATEMIA; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; METASTATIC BREAST CANCER; MUCOSA INFLAMMATION; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PREMEDICATION; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RASH; RESPONSE EVALUATION CRITERIA IN SOLID TUMORS; THROMBOCYTOPENIA; TREATMENT RESPONSE; TRIPLE NEGATIVE BREAST CANCER; URINARY TRACT INFECTION; ANALOGS AND DERIVATIVES; BIOSYNTHESIS; BREAST NEOPLASMS, MALE; CLINICAL TRIAL; IMMUNOLOGY; METABOLISM; METASTASIS; MIDDLE AGED; TRIPLE NEGATIVE BREAST NEOPLASMS; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIGENS, NEOPLASM; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS, MALE; CAMPTOTHECIN; CELL ADHESION MOLECULES; FEMALE; HUMANS; IMMUNOCONJUGATES; MALE; MIDDLE AGED; NEOPLASM METASTASIS; TRIPLE NEGATIVE BREAST NEOPLASMS;

EID: 85021706262     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2016.70.8297     Document Type: Article

References (43)

1. Sledge GW, Mamounas EP, Hortobagyi GN, et al: Past, present, and future challenges in breast cancer treatment. J Clin Oncol 32:1979-1986, 2014.
2. Torre LA, Bray F, Siegel RL, et al: Global cancer statistics, 2012. CA Cancer J Clin 65:87-108, 2015.
3. Perou CM, Sørlie T, Eisen MB, et al: Molecular portraits of human breast tumours. Nature 406: 747-752, 2000.
4. Carey LA, Perou CM, Livasy CA, et al: Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA 295:2492-2502, 2006.
5. Hurvitz S, Mead M: Triple-negative breast cancer: Advancements in characterization and treatment approach. Curr Opin Obstet Gynecol 28: 59-69, 2016.
6. Keenan T, Moy B, Mroz EA, et al: Comparison of the genomic landscape between primary breast cancer in African American versus white women and the association of racial differences with tumor recurrence. J Clin Oncol 33:3621-3627, 2015.
7. Rugo HS, Olopade OI, DeMichele A, et al: Adaptive randomization of veliparib-carboplatin treatment in breast cancer. N Engl J Med 375:23-34, 2016.
8. André F, Zielinski CC: Optimal strategies for the treatment of metastatic triple-negative breast cancer with currently approved agents. Ann Oncol 23:vi46-vi51, 2012 (suppl 6).
9. Dent R, Trudeau M, Pritchard KI, et al: Triplenegative breast cancer: Clinical features and patterns of recurrence. Clin Cancer Res 13:4429-4434, 2007.
10. Forero-Torres A, Varley KE, Abramson VG, et al: TBCRC 019: A phase II trial of nanoparticle albumin-bound paclitaxel with or without the antideath receptor 5 monoclonal antibody tigatuzumab in patients with triple-negative breast cancer. Clin Cancer Res 21:2722-2729, 2015.
11. Isakoff SJ, Mayer EL, He L, et al: TBCRC009: A multicenter phase II clinical trial of platinum monotherapywith biomarker assessment inmetastatic triplenegative breast cancer. J Clin Oncol 33:1902-1909, 2015.
12. Lin NU, Vanderplas A, Hughes ME, et al: Clinicopathologic features, patterns of recurrence, and survival among women with triple-negative breast cancer in the National Comprehensive Cancer Network. Cancer 118:5463-5472, 2012.
13. O'Shaughnessy J, Schwartzberg L, Danso MA, et al: Phase III study of iniparib plus gemcitabine and carboplatin versus gemcitabine and carboplatin in patients with metastatic triple-negative breast cancer. J Clin Oncol 32:3840-3847, 2014.
14. Perez EA, Patel T, Moreno-Aspitia A: Efficacy of ixabepilone in ER/PR/HER2-negative (triple-negative) breast cancer. Breast Cancer Res Treat 121:261-271, 2010.
15. Cardoso F, Costa A, Norton L, et al: ESO-ESMO 2nd International Consensus Guidelines for Advanced Breast Cancer (ABC2). Breast 23:489-502, 2014.
16. Cardillo TM, Govindan SV, Sharkey RM, et al: Sacituzumab govitecan (IMMU-132), an anti-Trop-2/SN-38 antibody-drug conjugate: Characterization and efficacy in pancreatic, gastric, and other cancers. Bioconjug Chem 26:919-931, 2015.
17. Cardillo TM, Govindan SV, Sharkey RM, et al: Humanized anti-Trop-2 IgG-SN-38 conjugate for effective treatment of diverse epithelial cancers: Preclinical studies in human cancer xenograft models and monkeys. Clin Cancer Res 17:3157-3169, 2011.
18. Goldenberg DM, Cardillo TM, Govindan SV, et al: Trop-2 is a novel target for solid cancer therapy with sacituzumab govitecan (IMMU-132), an antibodydrug conjugate (ADC). Oncotarget 6:22496-22512, 2015.
19. Shvartsur A, Bonavida B: Trop2 and its overexpression in cancers: Regulation and clinical/therapeutic implications. Genes Cancer 6:84-105, 2015.
20. Ambrogi F, Fornili M, Boracchi P, et al: Trop-2 is a determinant of breast cancer survival. PLoS One 9:e96993, 2014 [Erratum: PLoS One 9:e110606, 2014].
21. Lipinski M, Parks DR, Rouse RV, et al: Human trophoblast cell-surface antigens defined by monoclonal antibodies. Proc Natl Acad Sci U S A 78:5147-5150, 1981.
22. Stepan LP, Trueblood ES, Hale K, et al: Expression of Trop2 cell surface glycoprotein in normal and tumor tissues: Potential implications as a cancer therapeutic target. J Histochem Cytochem 59: 701-710, 2011.
23. Basu A, Goldenberg DM, Stein R: The epithelial/carcinoma antigen EGP-1, recognized by monoclonal antibody RS7-3G11, is phosphorylated on serine 303. Int J Cancer 62:472-479, 1995.
24. Wang J, Day R, Dong Y, et al: Identification of Trop-2 as an oncogene and an attractive therapeutic target in colon cancers. Mol Cancer Ther 7:280-285, 2008.
25. Lin H, Huang JF, Qiu JR, et al: Significantly upregulated TACSTD2 and cyclin D1 correlate with poor prognosis of invasive ductal breast cancer. Exp Mol Pathol 94:73-78, 2013.
26. Rothenberg ML: Topoisomerase I inhibitors: Review and update. Ann Oncol 8:837-855, 1997.
27. Hayashi H, Tsurutani J, Satoh T, et al: Phase II study of bi-weekly irinotecan for patients with previously treated HER2-negative metastatic breast cancer: KMBOG0610B. Breast Cancer 20:131-136, 2013.
28. Perez EA, Hillman DW, Mailliard JA, et al: Randomized phase II study of two irinotecan schedules for patients with metastatic breast cancer refractory to an anthracycline, a taxane, or both. J Clin Oncol 22:2849-2855, 2004.
29. Mathijssen RH, van Alphen RJ, Verweij J, et al: Clinical pharmacokinetics and metabolism of irinotecan (CPT-11). Clin Cancer Res 7:2182-2194, 2001.
30. Sharkey RM, McBride WJ, Cardillo TM, et al: Enhanced delivery of SN-38 to human tumor xenografts with an anti-Trop-2-SN-38 antibody conjugate (sacituzumab govitecan). Clin Cancer Res 21: 5131-5138, 2015.
31. Starodub AN, Ocean AJ, Shah MA, et al: Firstin- human trial of a novel anti-Trop-2 antibody-SN-38 conjugate, sacituzumab govitecan, for the treatment of diverse metastatic solid tumors. Clin Cancer Res 21:3870-3878, 2015.
32. Hammond MEH, Hayes DF, Dowsett M, et al: American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J Clin Oncol 28:2784-2795, 2010.
33. Wolff AC, Hammond MEH, Hicks DG, et al: Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. J Clin Oncol 31:3997-4013, 2013.
34. Medical Dictionary for Regulatory Activities version 10, www.meddra.org.
35. Govindan SV, Sharkey RM, Goldenberg DM: Prospects and progress of antibody-drug conjugates in solid tumor therapies. Expert Opin Biol Ther 16: 883-893, 2016.
36. Sievers EL, Senter PD: Antibody-drug conjugates in cancer therapy. Annu Rev Med 64:15-29, 2013.
37. Slamon DJ, Leyland-Jones B, Shak S, et al: Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344:783-792, 2001.
38. Verma S, Miles D, Gianni L, et al: Trastuzumab emtansine for HER2-positive advanced breast cancer. N Engl J Med 367:1783-1791, 2012.
39. Xie R, Mathijssen RH, Sparreboom A, et al: Clinical pharmacokinetics of irinotecan and its metabolites in relation with diarrhea. Clin Pharmacol Ther 72:265-275, 2002.
40. Stein R, Chen S, Sharkey RM, et al: Murine monoclonal antibodies raised against human non-small cell carcinoma of the lung: Specificity and tumor targeting. Cancer Res 50:1330-1336, 1990.
41. Cubas R, Li M, Chen C, et al: Trop2: A possible therapeutic target for late stage epithelial carcinomas. Biochim Biophys Acta 1796:309-314, 2009.
42. Stein R, Basu A, Chen S, et al: Specificity and properties of MAb RS7-3G11 and the antigen defined by this pancarcinoma monoclonal antibody. Int J Cancer 55:938-946, 1993.
43. Trerotola M, Cantanelli P, Guerra E, et al: Upregulation of Trop-2 quantitatively stimulates human cancer growth. Oncogene 32:222-233, 2013.